Covered recipient · General Payments record
MARNELLE CHERY
General Payments · PY2023–2024
$549.52
- Reported across 19 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $438.37 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $132.95 | 8 |
| BOSTON SCIENTIFIC CORPORATION | $116.83 | 2 |
| Neurocrine BioSciences, Inc. | $57.75 | 2 |
| UCB, Inc. | $49.20 | 1 |
| Janssen Pharmaceuticals, Inc | $39.45 | 2 |
| Indivior Inc. | $28.08 | 1 |
| Otsuka America Pharmaceutical, Inc. | $14.11 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
Program year 2024 2023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $18.55 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103457186 | CMS |
| ABBVIE INC. | $17.83 | 02/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103457188 | CMS |
| ABBVIE INC. | $16.46 | 02/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103457190 | CMS |
| ABBVIE INC. | $21.17 | 05/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103457192 | CMS |
| ABBVIE INC. | $13.54 | 07/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103457194 | CMS |
| ABBVIE INC. | $14.51 | 08/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103457196 | CMS |
| ABBVIE INC. | $15.73 | 11/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103457198 | CMS |
| ABBVIE INC. | $15.16 | 12/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103457200 | CMS |
| Boston Scientific Corporation | $30.69 | 03/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1092427771 | CMS |
| Boston Scientific Corporation | $86.14 | 05/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1092427773 | CMS |
| Indivior Inc. | $28.08 | 05/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144525852 | CMS |
| Janssen Pharmaceuticals, Inc | $18.25 | 07/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1077967946 | CMS |
| Janssen Pharmaceuticals, Inc | $21.20 | 09/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1077967542 | CMS |
| Neurocrine Biosciences, Inc. | $30.24 | 06/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150825508 | CMS |
| Neurocrine Biosciences, Inc. | $27.51 | 07/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150832522 | CMS |
| Otsuka America Pharmaceutical, Inc. | $14.11 | 09/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118874964 | CMS |
| UCB, Inc. | $49.20 | 02/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143024287 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2023, 2024
- Source files
- Dataset page · Bulk file · PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.